Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis
This study has been completed.
Study NCT00010426   Information provided by FDA Office of Orphan Products Development
First Received: February 2, 2001   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystinosis
More general conditions related to this trial
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Interventions listed in this trial
cysteamine hydrochloride
Additional drug interventions recognized in this trial
Cysteamine
More general drug interventions related to this trial
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents
Sponsors listed in this trial
FDA Office of Orphan Products Development
Sigma Tau Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services